Abstract
Supplemental Figure 4: A. Bar plot showing shared and unshared mutations between pre- and post-treatment samples. B. Oncoprint comparing pre- and post-treatment samples in ERBB2, FGFR2, and BRAF treatment cohorts. C. Lollipop plots for specific mutations in KRAS and MAP2K1 detected in the sequential samples from the BRAF targeted therapy-treated patient.